Q-omics provides the consensus-scored MT1H profile across patient tissues and cancer cell-line models. MT1H expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MT1H is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MT1H RNA expression shows 16,270 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where MT1H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1H survival associations across molecular data types. MT1H RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1H RNA expression–survival associations across cancer types. High MT1H expression shows unfavorable associations in ACC, KIRC, KICH, BRCA and UVM, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MT1H RNA expression.
This table summarizes MT1H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MT1H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1H shows lower tumor expression in KIRC, KICH, THCA, KIRP, COAD and LIHC. The KIRC box plot shows higher MT1H RNA expression in normal versus tumor tissue (log2 FC = −6.168, t-test p < 0.001).
This table shows molecular features associated with MT1H in patient tissues and cancer cell lines. In patient samples, MT1H shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MT1H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
